Retrieve available abstracts of 172 articles: HTML format
Single Articles
August 2025
VAN AMMERS M, Tracey T, Yazdabadi A, Ciconte A, et al A survey of skin check rates in an outpatient oncology melanoma clinic.
Melanoma Res. 2025;35:290-291. PubMed
July 2025
CHAI Y, Zhao J, Wang X, Li B, et al Upregulation of SFTPC gene expression is associated with disease progression and
worse survival outcomes in human skin melanomas.
Melanoma Res. 2025 Jul 1. doi: 10.1097/CMR.0000000000001051. PubMedAbstract available
June 2025
KRISTJANSEN KA, Birk-Sorensen L, Bonnelykke-Behrndtz ML Perioperative neutrophil-to-lymphocyte ratio in patients with melanoma: a pilot
study assessing surgical stress after sentinel lymph node biopsy.
Melanoma Res. 2025 Jun 26. doi: 10.1097/CMR.0000000000001052. PubMedAbstract available
PANDIT-TASKAR N, Mauguen A, Frosina D, Jungbluth A, et al Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study.
Melanoma Res. 2025 Jun 25. doi: 10.1097/CMR.0000000000001050. PubMedAbstract available
KREUZ M, Moraes FCA, Lobo AOM, Skov RPH, et al Updated meta-analysis on the risk of melanoma associated with phosphodiesterase
type 5 inhibitors.
Melanoma Res. 2025 Jun 6. doi: 10.1097/CMR.0000000000001049. PubMedAbstract available
BERKAOUI I, Zourdani L, Janela-Lapert R Postimmunotherapy antiglial fibrillary acidic protein encephalomyelitis after
adjuvant pembrolizumab for melanoma.
Melanoma Res. 2025 Jun 4. doi: 10.1097/CMR.0000000000001048. PubMedAbstract available
CHAVERON M, Toulemonde E, Desmedt E, Boileau M, et al Resolution of diffuse cuticular melanosis under immunotherapy in a patient with
metastatic melanoma.
Melanoma Res. 2025;35:213-215. PubMed
May 2025
BERTOLLI E, Micheletti SB, de Camargo VP, da Silva TV, et al Nomograms versus artificial intelligence platforms: which one can better predict
sentinel node positivity in melanoma patients?
Melanoma Res. 2025 May 27. doi: 10.1097/CMR.0000000000001047. PubMedAbstract available
KREUZ M, de Souza Wagner PH, Tanimoto LE, da Rosa VA, et al Melanoma and pregnant women: a systematic review and meta-analysis.
Melanoma Res. 2025 May 27. doi: 10.1097/CMR.0000000000001043. PubMedAbstract available
BLOHOWIAK RF, Welch NW, Rigden BW, Varman RM, et al Evaluation of surgical modalities for stage 0 to stage II acral lentiginous
melanoma: a National Cancer Database study.
Melanoma Res. 2025 May 27. doi: 10.1097/CMR.0000000000001046. PubMedAbstract available
MYNAM RS, Menon N, Birbrair A, Ma VT, et al Successful use of nivolumab and relatlimab as salvage therapy for metastatic
uveal melanoma.
Melanoma Res. 2025 May 27. doi: 10.1097/CMR.0000000000001045. PubMedAbstract available
VAN RYAN V, Zahrieh D, Strand C, Churchill RA, et al Impact of systemic imaging surveillance on survival from metastatic uveal
melanoma.
Melanoma Res. 2025 May 19. doi: 10.1097/CMR.0000000000001042. PubMedAbstract available
PALACIOS-DIAZ RD, de Unamuno-Bustos B, Carratala-Garcia A, Perez-Simo G, et al Circulating tumor DNA predicts tumor progression and poor survival in patients
with stage III melanoma.
Melanoma Res. 2025 May 19. doi: 10.1097/CMR.0000000000001041. PubMedAbstract available
April 2025
JOERGER M, Diem S, Wyss N, Koster KL, et al Open-label nonrandomized phase IB study to characterize the safety and
recommended dose of tinostamustine in combination with nivolumab in patients with
advanced melanoma (ENIgMA).
Melanoma Res. 2025 Apr 17. doi: 10.1097/CMR.0000000000001040. PubMedAbstract available
ACAR C, Yuksel HC, Sahin G, Acar FP, et al C-reactive protein kinetics as prognostic biomarkers in advanced melanoma treated
with immune checkpoint inhibitors.
Melanoma Res. 2025 Apr 8. doi: 10.1097/CMR.0000000000001039. PubMedAbstract available
MATTEI J, Trindade EN, Chedid MF Mucosal melanoma: from molecular landscape to current treatment strategies:
Erratum.
Melanoma Res. 2025;35:153. PubMed
MARSIGLIO J, McPherson J, Wahl M, Hu-Lieskovan S, et al Pembrolizumab-induced acquired lipodystrophy: a case report and review of the
literature.
Melanoma Res. 2025;35:109-114. PubMedAbstract available
DAVIDSON SJ, Teoh DGK, Dudek AZ, Vogel RI, et al Immunotherapy for treatment of female genital tract melanoma: National Cancer
Database analysis.
Melanoma Res. 2025 Apr 1. doi: 10.1097/CMR.0000000000001036. PubMedAbstract available
PEDERSEN S, Borch TH, Svane IM, Donia M, et al Steroid-refractory severe immune-related mucositis following adjuvant anti-PD-1
therapy for resectable melanoma: a case report.
Melanoma Res. 2025 Apr 1. doi: 10.1097/CMR.0000000000001037. PubMedAbstract available
March 2025
BUJA A, Rugge M, Formaro CM, Grotto G, et al A real-world direct cost associated with a 4-year postdiagnosis follow-up in a
population-based cohort of patients with melanoma by clinical-pathological
characteristics.
Melanoma Res. 2025 Mar 28. doi: 10.1097/CMR.0000000000001033. PubMedAbstract available
HINNEN C, Tijssens F, von Haeseler E, van de Berg S, et al Do cortisol and psychological distress levels impact the effectiveness of
immunotherapy in patients with metastasized melanoma? A pilot study.
Melanoma Res. 2025 Mar 25. doi: 10.1097/CMR.0000000000001035. PubMedAbstract available
GUYON M, Faure M, Pernot M, Pham-Ledard A, et al Management of cardiac metastases of melanoma in the era of immunotherapy: a case
series.
Melanoma Res. 2025 Mar 25. doi: 10.1097/CMR.0000000000001032. PubMedAbstract available
TAS F, Ahishali E, Taskin OC Nivolumab-induced immune-mediated acute gastritis in a melanoma patient.
Melanoma Res. 2025 Mar 21. doi: 10.1097/CMR.0000000000001034. PubMedAbstract available
February 2025
JANSSEN S, Moufarrej A, Springer R, Haberle L, et al Diffuse large B-cell lymphoma mimicking metastatic melanoma: the importance of
biopsies in the era of immune checkpoint inhibitors.
Melanoma Res. 2025 Feb 27. doi: 10.1097/CMR.0000000000001028. PubMedAbstract available
GUGLIELMO A, De Benedittis A, Buligan C, Zelin E, et al Multiple primary melanomas in Udine, northeastern Italy: a focus on epidemiology
and new risk factors.
Melanoma Res. 2025 Feb 27. doi: 10.1097/CMR.0000000000001029. PubMedAbstract available
BEITNER A, Abu-Abeid A, Dayan D, Gat A, et al Patterns of expression and prognostic implication of glycoprotein nonmetastatic
protein B (GPNMB) expression in sentinel lymph nodes of melanoma patients.
Melanoma Res. 2025 Feb 14. doi: 10.1097/CMR.0000000000001019. PubMedAbstract available
AMRANE K, Le Noac'h P, Hemon P, Abgral R, et al MHC class II: a predictor of outcome in melanoma treated with immune checkpoint
inhibitors.
Melanoma Res. 2025 Feb 12. doi: 10.1097/CMR.0000000000001022. PubMedAbstract available
GONZALEZ-BARRALLO I, Castellon Rubio VE, Medina J, Espana Fernandez S, et al Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF
V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world
ELDERLYMEL study.
Melanoma Res. 2025 Feb 7. doi: 10.1097/CMR.0000000000001020. PubMedAbstract available
KERKOUR T, Meijers RWJ, Hollestein LM, Jansen AML, et al Genetic concordance in melanoma: insights from primary tumors and their matched
distant metastases.
Melanoma Res. 2025 Feb 6. doi: 10.1097/CMR.0000000000001024. PubMedAbstract available
TAS F, Erturk K Brain metastases during follow-up of patients with resected cutaneous melanoma.
Melanoma Res. 2025 Feb 4. doi: 10.1097/CMR.0000000000001026. PubMedAbstract available
BHATT KA, Vaynrub AJ, Cham J, Iyer SG, et al Diagnosis and management of concurrent metastatic melanoma and chronic
myelomonocytic leukemia.
Melanoma Res. 2025 Feb 4. doi: 10.1097/CMR.0000000000001025. PubMedAbstract available
SHEN YC, Huang YL, Kang YN, Chiu WK, et al Effectiveness and safety of talimogene laherparepvec and granulocyte-macrophage
colony-stimulating factor for metastatic melanoma: a systematic review and
network meta-analysis of randomized controlled trials.
Melanoma Res. 2025;35:60-66. PubMedAbstract available
January 2025
ANGELL CD, Sun SH, Lapurga G, Benner B, et al A comparison of myeloid-derived suppressor cell populations in patients with
ulcerated vs non-ulcerated melanoma receiving immune checkpoint blockade.
Melanoma Res. 2025 Jan 29. doi: 10.1097/CMR.0000000000001023. PubMedAbstract available
CHEN L, Cai B, Ni X, Lin Q, et al Temozolomide monotherapy versus combination therapies in melanoma: a
meta-analysis of efficacy and safety.
Melanoma Res. 2025 Jan 28. doi: 10.1097/CMR.0000000000001021. PubMedAbstract available
BASSI V, Apuzzi V, Vanella V, Facchini BA, et al SIAD onset in a patient affected by metastatic melanoma treated with immune
checkpoint inhibitors: the role of nivolumab treatment.
Melanoma Res. 2025 Jan 7. doi: 10.1097/CMR.0000000000001017. PubMed
POZUELO-RUIZ M, de Unamuno-Bustos B, Palacios-Diaz RD, Blanes-Martinez MDM, et al Vitiligo-like hypopigmentation secondary to adjuvant checkpoint inhibitor therapy
in patients with resectable stage III melanoma: a cohort from two tertiary
hospitals.
Melanoma Res. 2025 Jan 7. doi: 10.1097/CMR.0000000000001018. PubMedAbstract available
December 2024
AL-NAESAN I, Krepper D, Sparano F, Sztankay M, et al Patient-reported outcomes in randomized controlled trials evaluating BRAF
inhibitors in patients with cutaneous melanoma: a systematic scoping review of
quality of reporting and trial results.
Melanoma Res. 2024 Dec 11. doi: 10.1097/CMR.0000000000001014. PubMedAbstract available
LEIBOVIT-REIBEN Z, Godfrey H, Jedlowski P, Thiede R, et al Neurologic adverse events associated with BRAF and MEK inhibitor therapy in
patients with malignant melanoma: a disproportionality analysis using the Food
and Drug Administration Adverse Event Reporting System.
Melanoma Res. 2024 Dec 6. doi: 10.1097/CMR.0000000000001015. PubMedAbstract available
ESMAELI B, Ogden T, Nichols M, Lu T, et al Rate of response to immune checkpoint inhibitor therapy in patients with
conjunctival melanoma.
Melanoma Res. 2024 Dec 6. doi: 10.1097/CMR.0000000000001016. PubMedAbstract available
WITTEVEEN SJ, Klop WMC, van Dijk-de Haan MC, Karssemakers LHE, et al Melanoma in the head and neck region: the value of preoperative imaging in
melanoma stage I-II.
Melanoma Res. 2024 Dec 3. doi: 10.1097/CMR.0000000000001013. PubMedAbstract available
HORISAKI K, Yoshikawa S, Omata W, Tsutsumida A, et al Clinical features of vulvar and vaginal malignant melanomas and the effects of
immune checkpoint inhibitors in Japanese patients: a single-center, retrospective
cohort study.
Melanoma Res. 2024 Dec 3. doi: 10.1097/CMR.0000000000001012. PubMedAbstract available
BURSHTEIN J, Shah M, Zakria D, Rigel D, et al The association between dermatologist density and melanoma prognosis using
melanoma mortality-incidence ratio.
Melanoma Res. 2024;34:550-552. PubMed
ARJUNAN A, Wardrop M, Malek MM, Davit AJ 3rd, et al Treatment outcomes following partial shave biopsy of atypical and malignant
melanocytic tumors in pediatric patients.
Melanoma Res. 2024;34:544-548. PubMedAbstract available
November 2024
NIU L, Liu S, Shen J, Chang J, et al ATF3 regulates CDC42 transcription and influences cytoskeleton remodeling, thus
inhibiting the proliferation, migration and invasion of malignant skin melanoma
cells.
Melanoma Res. 2024 Nov 26. doi: 10.1097/CMR.0000000000001011. PubMedAbstract available
MACAIRE C, Lefevre W, Dalac S, Montaudie H, et al Real-life effectiveness on overall survival of continued immune checkpoint
inhibition following progression in advanced melanoma: estimation from the
Melbase cohort.
Melanoma Res. 2024 Nov 11. doi: 10.1097/CMR.0000000000000973. PubMedAbstract available
October 2024
ZHENG L, Susanto AK, Soyer HP, Janda M, et al Psychosocial wellbeing in people with melanoma in-situ: a systematic review.
Melanoma Res. 2024 Oct 10. doi: 10.1097/CMR.0000000000001007. PubMedAbstract available
KREUZ M, de Moraes FCA, Sano VKT, Westphal Filho FL, et al Association of baseline neutrophil-to-lymphocyte ratio and prognosis in melanoma
patients treated with PD-1/PD-L1 blockade: a systematic review and meta-analysis.
Melanoma Res. 2024 Oct 8. doi: 10.1097/CMR.0000000000001006. PubMedAbstract available
CAMPILLO P, Kesler A, Ramirez CA, Ramirez CJ, et al International incidence of melanoma in heart transplant recipients: a
meta-analysis.
Melanoma Res. 2024 Oct 7. doi: 10.1097/CMR.0000000000001008. PubMedAbstract available
PAOLINO G, Podo Brunetti A, De Rosa C, Cantisani C, et al Anorectal melanoma: systematic review of the current literature of an aggressive
type of melanoma.
Melanoma Res. 2024 Oct 4. doi: 10.1097/CMR.0000000000001003. PubMedAbstract available
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and
local radiation therapy to activate immune rejection of spontaneous canine
melanoma: Erratum.
Melanoma Res. 2024;34:473. PubMed
MATTIUZZI C, Lippi G The death rate for melanoma remained unchanged in the USA during the coronavirus
disease 2019 pandemic.
Melanoma Res. 2024;34:472. PubMed
September 2024
NACCHIERO E, Giotta M, Robusto F, Metta ME, et al The role of wide local excision of a primary lesion in cutaneous malignant
melanoma: a retrospective analysis of its usefulness in local and general control
of disease.
Melanoma Res. 2024 Sep 25. doi: 10.1097/CMR.0000000000000999. PubMedAbstract available
STAWIARZ M, Hoang MP, Kowalik A High-resolution RNA-sequencing reveals TRIM33::CSDE1 gene fusion in metastasizing
vulvar melanoma.
Melanoma Res. 2024 Sep 18. doi: 10.1097/CMR.0000000000001005. PubMedAbstract available
MCKECHNIE T, Talwar G, Grewal S, Wang A, et al The impact of statins on melanoma survival: a systematic review and
meta-analysis.
Melanoma Res. 2024 Sep 12. doi: 10.1097/CMR.0000000000001001. PubMedAbstract available
August 2024
STOFF R, Markovic SN, McWilliams RR, Kottschade LA, et al Real-world evidence on efficacy and toxicity of targeted therapy in older
melanoma patients treated in a tertiary-hospital setting.
Melanoma Res. 2024 Aug 30. doi: 10.1097/CMR.0000000000000997. PubMedAbstract available
KIM I, Oh J, Yoon S, Han MY, et al Pediatric melanoma incidence and survival: a fifteen-year nationwide
retrospective cohort study in Korea (2004-2019).
Melanoma Res. 2024 Aug 30. doi: 10.1097/CMR.0000000000001000. PubMedAbstract available
ZWEEDIJK BE, Schurink AW, van Dalen T, van Ginhoven TM, et al Transcutaneous sentinel lymph node detection in skin melanoma with near-infrared
fluorescence imaging using indocyanine green.
Melanoma Res. 2024 Aug 2. doi: 10.1097/CMR.0000000000000994. PubMedAbstract available
WANG S, Zhou H, Ma Y, Jin S, et al A retrospective study of clinicopathological and prognostic characteristics in
177 Chinese patients with acral melanoma: heterogeneity based on tumor site.
Melanoma Res. 2024;34:390-392. PubMed
KIBBIE JJ, Zita SM, Dellavalle RP, Dunnick CA, et al The number needed to biopsy for cutaneous melanoma in academic dermatology
clinics.
Melanoma Res. 2024;34:350-354. PubMedAbstract available
ORLANDI E, Ceccuzzi L, Belpinati F, Rodolfo M, et al Sex-dependent interaction of PTGS2 with miR-146a as risk factor for melanoma and
the impact of sex hormones in gene expression in skin cells.
Melanoma Res. 2024;34:296-306. PubMedAbstract available
OZLUK AA, Gunenc D, Yildirim SS, Karaca B, et al Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity:
a case series and review of the literature.
Melanoma Res. 2024;34:335-342. PubMedAbstract available
July 2024
ZHANG S, Liu Z, Zhu D Development and validation of prognostic nomogram in pediatric melanoma: a
population-based study.
Melanoma Res. 2024 Jul 31. doi: 10.1097/CMR.0000000000000993. PubMedAbstract available
ELMES JB, Davis JM, Musselwhite LW, Chiad Z, et al Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient
with metastatic melanoma: a case report and pharmacovigilance analysis.
Melanoma Res. 2024 Jul 22. doi: 10.1097/CMR.0000000000000992. PubMedAbstract available
TSIMPIDAKIS A, Koumprentziotis IA, Mastoraki E, Plaka M, et al Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma
patient: a case report and mechanistic insight.
Melanoma Res. 2024 Jul 22. doi: 10.1097/CMR.0000000000000991. PubMedAbstract available
CHANDRASEKARAN S, Ling YL, Tang J Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant
treatment of BRAF-mutated melanoma patients in the United States.
Melanoma Res. 2024 Jul 16. doi: 10.1097/CMR.0000000000000990. PubMedAbstract available
FOKKEN C, Silbern I, Shomroni O, Pan KT, et al Interfering with aggregated alpha-synuclein in advanced melanoma leads to a major
upregulation of MHC class II proteins.
Melanoma Res. 2024 Jul 2. doi: 10.1097/CMR.0000000000000982. PubMedAbstract available
June 2024
LOCHRIN SE, Cugliari MK, Yeh R, Shoushtari AN, et al Efficacy of axitinib in a US cohort of patients with programmed cell death
protein 1-resistant mucosal melanoma.
Melanoma Res. 2024 Jun 28. doi: 10.1097/CMR.0000000000000988. PubMedAbstract available
DE GIORGI V, Cecchi G, Perillo G, Zuccaro B, et al Synchronous double primary vulvar melanoma: a not so rare possibility. A clinical
and dermoscopic case study.
Melanoma Res. 2024 Jun 24. doi: 10.1097/CMR.0000000000000989. PubMedAbstract available
ASHER N, Bar-Hai N, Ben-Betzalel G, Stoff R, et al Exploring the clinical significance of specific immune-related adverse events in
melanoma patients undergoing immune checkpoint inhibitor therapy.
Melanoma Res. 2024 Jun 24. doi: 10.1097/CMR.0000000000000985. PubMedAbstract available
SHEMER M, Shimonovitz M, Furer R, Abu-Abeid A, et al Long-term outcomes and patterns of recurrence in patients with thin melanoma and
a negative sentinel lymph node biopsy: a single-center experience.
Melanoma Res. 2024 Jun 14. doi: 10.1097/CMR.0000000000000986. PubMedAbstract available
BUSTAMANTE P, Coblentz J, Mastromonaco C, Youhnovska E, et al Comprehensive clinical imaging, histopathological analysis and liquid
biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft
model.
Melanoma Res. 2024 Jun 7. doi: 10.1097/CMR.0000000000000964. PubMedAbstract available
LIU H, Jiang H, Shan Q Reflectance confocal microscopy versus dermoscopy for the diagnosis of cutaneous
melanoma: a head-to-head comparative meta-analysis.
Melanoma Res. 2024 Jun 7. doi: 10.1097/CMR.0000000000000980. PubMedAbstract available
LUO P, Guo R, Gao D, Zhang Q, et al Causal relationship between sex hormones and cutaneous melanoma: a two-sample
Mendelian randomized study.
Melanoma Res. 2024 Jun 5. doi: 10.1097/CMR.0000000000000983. PubMedAbstract available
DINI F, Susini P, Zuccaro B, Nisi G, et al Head and neck melanoma: the eyelid region has a better prognosis and easier
management: a retrospective survey and systematic review.
Melanoma Res. 2024 Jun 3. doi: 10.1097/CMR.0000000000000984. PubMedAbstract available
SHAH H, Parisi R, Everdell E, Feustel P, et al The effect of COVID-19 on early melanoma detection.
Melanoma Res. 2024;34:283-284. PubMed
May 2024
SAMLOWSKI W, Silver MA, Hohlbauch A, Zhang S, et al Relationships between survival and real-world recurrence-free survival or distant
metastasis-free survival among patients with completely resected stage IIB or IIC
melanoma.
Melanoma Res. 2024 May 27. doi: 10.1097/CMR.0000000000000962. PubMedAbstract available
VANDER MIJNSBRUGGE AS, Cerckel J, Dirven I, Tijtgat J, et al Regorafenib in patients with pretreated advanced melanoma: a single-center case
series.
Melanoma Res. 2024 May 27. doi: 10.1097/CMR.0000000000000977. PubMedAbstract available
INDINI A, Gueli R, Cerati M, Rijavec E, et al Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and
nivolumab in a patient with melanoma.
Melanoma Res. 2024 May 20. doi: 10.1097/CMR.0000000000000981. PubMedAbstract available
ALBERTINI MR, Zuleger CL, Ranheim EA, Shiyanbola O, et al Administration of intratumoral GD2-directed interleukin-2 immunocytokine and
local radiation therapy to activate immune rejection of spontaneous canine
melanoma.
Melanoma Res. 2024 May 20. doi: 10.1097/CMR.0000000000000975. PubMedAbstract available
April 2024
GAO Y, Wang Y, Luo Y, Zhang Y, et al Pretreatment CD8+PD-1+ to CD4+PD-1+ ratio is associated with the prognosis of
advanced melanoma patients treated with PD-1 inhibitors.
Melanoma Res. 2024 Apr 22. doi: 10.1097/CMR.0000000000000972. PubMedAbstract available
WU LW, Tao JJ, McDonnell D, Izar B, et al Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and
LAG-3 inhibition.
Melanoma Res. 2024 Apr 18. doi: 10.1097/CMR.0000000000000974. PubMedAbstract available
SUWAJANAKORN D, Lane AM, Go AK, Hartley CD, et al Impact of gene expression profiling on diagnosis and survival after metastasis in
patients with uveal melanoma.
Melanoma Res. 2024 Apr 5. doi: 10.1097/CMR.0000000000000971. PubMedAbstract available
HENNEMANN A, Puzenat E, Decreuse M, Vuillier F, et al Intracranial hemorrhage caused by dabrafenib and trametinib therapy for
metastatic melanoma.
Melanoma Res. 2024 Apr 5. doi: 10.1097/CMR.0000000000000820. PubMedAbstract available
MAIONE V, Perantoni M, Bettolini L, Bighetti S, et al Influence of regression, its extent and tumor-infiltrating lymphocytes on
sentinel node status, relapse, and survival in a 10-year retrospective study of
melanoma patients.
Melanoma Res. 2024 Apr 2. doi: 10.1097/CMR.0000000000000970. PubMedAbstract available
March 2024
KODALI N, Bhattaru A, Blanchard I, Sharma Y, et al Assessing melanoma prognosis: the interplay between patient profiles, survival,
and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.
Melanoma Res. 2024 Mar 29. doi: 10.1097/CMR.0000000000000968. PubMedAbstract available
FABRE M, Lamoureux A, Meunier L, Samaran Q, et al Efficiency and tolerance of second-line triple BRAF inhibitor/MEK
inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with
central nervous system metastases occurring during first-line combined targeted
therapy: a real-life survey.
Melanoma Res. 2024 Mar 28. doi: 10.1097/CMR.0000000000000963. PubMedAbstract available
NEKKANTI SS, Nusrath S, Jarang R, Rayani BK, et al Feasibility and efficacy of indocyanine green in monitoring systemic drug leakage
during isolated limb perfusion for recurrent melanoma of extremity.
Melanoma Res. 2024 Mar 15. doi: 10.1097/CMR.0000000000000967. PubMedAbstract available
LEROY M, Desmedt E, Deramoudt L, Vasseur M, et al Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose
every month: a real-life analysis of nivolumab in the treatment of advanced
melanoma.
Melanoma Res. 2024 Mar 15. doi: 10.1097/CMR.0000000000000965. PubMedAbstract available
WANG P, Liu T, Zhang Q, Luo P, et al Genetic causal relationship between gut microbiota and cutaneous melanoma: a
two-sample Mendelian randomization study.
Melanoma Res. 2024 Mar 11. doi: 10.1097/CMR.0000000000000960. PubMedAbstract available
NG CA, Luckett T, Mulhern B, Kee D, et al What matters most to people with metastatic uveal melanoma? A qualitative study
to inform future measurement of health-related quality of life.
Melanoma Res. 2024 Mar 5. doi: 10.1097/CMR.0000000000000961. PubMedAbstract available
February 2024
DE PINTO G, Mignozzi S, La Vecchia C, Levi F, et al Global trends in cutaneous malignant melanoma incidence and mortality.
Melanoma Res. 2024 Feb 21. doi: 10.1097/CMR.0000000000000959. PubMedAbstract available
TEIXEIRA RJ, de Souza VG, Sorroche BP, Paes VG, et al Immunohistochemistry assessment of tissue neutrophil-to-lymphocyte ratio (tNLR)
predicts outcomes in melanoma patients treated with anti-programmed cell death 1
therapy.
Melanoma Res. 2024 Feb 16. doi: 10.1097/CMR.0000000000000958. PubMedAbstract available
ZHANG W, Wang S Machine learning developed an intratumor heterogeneity signature for predicting
prognosis and immunotherapy benefits in skin cutaneous melanoma.
Melanoma Res. 2024 Feb 16. doi: 10.1097/CMR.0000000000000957. PubMedAbstract available
DE SMEDT J, Aura C, Van Kelst S, Janssen L, et al Clinical and genetic determinants of vitamin D receptor expression in cutaneous
melanoma patients.
Melanoma Res. 2024 Feb 13. doi: 10.1097/CMR.0000000000000929. PubMedAbstract available
DELZENNE G, Boileau M, Jamme P, Farchi O, et al Relevance of detection of RAF fusion transcripts in pan-negative melanoma in
routine practice.
Melanoma Res. 2024 Feb 7. doi: 10.1097/CMR.0000000000000955. PubMedAbstract available
ERCAN A, Yalcin CE Neonatal cutaneous melanoma with cutaneous metastasis: a case report and review
of literature.
Melanoma Res. 2024 Feb 7. doi: 10.1097/CMR.0000000000000956. PubMedAbstract available
DIAZ MJ, Quach J, Song J, Milanovic S, et al Hypoxic transcriptomes predict survival and tumor-infiltrating immune cell
composition in cutaneous melanoma.
Melanoma Res. 2024 Feb 7. doi: 10.1097/CMR.0000000000000938. PubMedAbstract available
GEIGER CE, Mrabet-Dahbi S, Berger I The BRAF and NRAS status among distinct metastases of malignant melanoma differ
significantly independent of tissue origin and temporal occurrence. Possible
effect on clinical relevance?
Melanoma Res. 2024;34:85-87. PubMed
ROSTER K, Thang C, Islam S, Lipner SR, et al Underreporting of acral lentiginous melanoma in studies informing American Joint
Committee on Cancer Staging System Guidelines: a review of 150 cited studies.
Melanoma Res. 2024;34:84-88. PubMed
DUARTE R, Trigo F, Luz I, Santos P, et al Small-vessel vasculitis leading to severe acute kidney injury after ipilimumab: a
case report.
Melanoma Res. 2024;34:76-79. PubMedAbstract available
January 2024
DAVIDSON TM, Hieken TJ, Glasgow AE, Habermann EB, et al Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 2020.
Melanoma Res. 2024 Jan 23. doi: 10.1097/CMR.0000000000000953. PubMedAbstract available
KOSTAKI M, Plaka M, Befon A, Dessinioti C, et al Simultaneous melanomas in the setting of multiple primary melanomas.
Melanoma Res. 2024 Jan 15. doi: 10.1097/CMR.0000000000000954. PubMedAbstract available
PARISA S, Amirhossein I, Hamed YS, Javad F, et al The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem
cells tumorigenicity.
Melanoma Res. 2024 Jan 15. doi: 10.1097/CMR.0000000000000931. PubMedAbstract available
KO B, Tao K, Brennan L, Rakhade S, et al Evaluating the efficacy of combination and single-agent immunotherapies in
real-world patterns of disease progression and survival of metastatic melanoma
patients.
Melanoma Res. 2024 Jan 5. doi: 10.1097/CMR.0000000000000945. PubMedAbstract available
December 2023
LOUVEAU B, Reger De Moura C, Jouenne F, Sadoux A, et al Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated
melanoma preclinical models.
Melanoma Res. 2023 Dec 22. doi: 10.1097/CMR.0000000000000950. PubMedAbstract available
YEE J, Rosendahl C, Aoude LG The role of artificial intelligence and convolutional neural networks in the
management of melanoma: a clinical, pathological, and radiological perspective.
Melanoma Res. 2023 Dec 22. doi: 10.1097/CMR.0000000000000951. PubMedAbstract available
ROSHARDT PRIETO NM, Turko P, Zellweger C, Nguyen-Kim TDL, et al Patterns of radiological response to tebentafusp in patients with metastatic
uveal melanoma.
Melanoma Res. 2023 Dec 19. doi: 10.1097/CMR.0000000000000952. PubMedAbstract available
YAN J, Wang H, Lu X, Li F, et al Development and validation of a nomogram for elderly patients with ulcerative
melanoma.
Melanoma Res. 2023 Dec 13. doi: 10.1097/CMR.0000000000000940. PubMedAbstract available
BAFALOUKOS D, Kouzis P, Gouveris P, Boukovinas I, et al Real-world management practices and characteristics of patients with advanced
melanoma initiated on immuno-oncology or targeted therapy in the first-line
setting during the period 2015-2018 in Greece. The 'SUMMER' study: a
retrospective multicenter ch
Melanoma Res. 2023 Dec 13. doi: 10.1097/CMR.0000000000000949. PubMedAbstract available
RICHTIG E, Nguyen VA, Koelblinger P, Wolf I, et al Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a
non-interventional, multicenter, prospective trial.
Melanoma Res. 2023 Dec 13. doi: 10.1097/CMR.0000000000000948. PubMedAbstract available
SWITZER B, Puzanov I, Gandhi S, Repasky EA, et al Targeting beta-adrenergic receptor pathways in melanoma: how stress modulates
oncogenic immunity.
Melanoma Res. 2023 Dec 4. doi: 10.1097/CMR.0000000000000943. PubMedAbstract available
PARISI R, Shah H, Everdell E, Feustel P, et al First-time office visit for suspicious skin lesion evaluation as a predictor of
high-risk melanoma.
Melanoma Res. 2023;33:555-556. PubMed
CARMONA-ROCHA E, Sullivan I, Yelamos O Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential
marker for clinical response.
Melanoma Res. 2023;33:553-555. PubMed
TAN SX, Chong S, Rowe C, Claeson M, et al pSTAT5 is associated with improved survival in patients with thick or ulcerated
primary cutaneous melanoma.
Melanoma Res. 2023;33:506-513. PubMedAbstract available
MEYER SN, Simmons E, Studer AC, Rauen KA, et al Melanocytic neoplasms in neurofibromatosis type 1: a systematic review.
Melanoma Res. 2023;33:437-446. PubMedAbstract available
VIGNESWARAN G, Malalasekera W, Smith V, Gibson T, et al Quality of life after melphalan percutaneous hepatic perfusion for patients with
metastatic Uveal Melanoma.
Melanoma Res. 2023 Dec 1. doi: 10.1097/CMR.0000000000000947. PubMedAbstract available
November 2023
STAHLIE EHA, Zijlker LP, Wouters MWJM, Schrage YM, et al Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients
with newly diagnosed and recurrent stage III melanoma.
Melanoma Res. 2023 Nov 28. doi: 10.1097/CMR.0000000000000946. PubMedAbstract available
MEZOLAKI NE, Baltas E, Ocsai HL, Varga A, et al Tumour regression predicts better response to interferon therapy in melanoma
patients: a retrospective single centre study.
Melanoma Res. 2023 Nov 13. doi: 10.1097/CMR.0000000000000935. PubMedAbstract available
KAHLER KC, Debus D, Schley G, Goppner D, et al Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients
with BRAF V600 mutant melanoma with and without cerebral metastasis under
real-world conditions in Germany: the non-interventional study coveNIS.
Melanoma Res. 2023 Nov 13. doi: 10.1097/CMR.0000000000000908. PubMedAbstract available
PAOLINO G, Carugno A, Rongioletti F, Ponzoni M, et al Bone marrow metastases: a systematic review of a neglected involvement in
malignant melanoma.
Melanoma Res. 2023 Nov 8. doi: 10.1097/CMR.0000000000000942. PubMedAbstract available
CHEN W, Yang C, Chen B, Xi M, et al Management of metastatic bone disease of melanoma.
Melanoma Res. 2023 Nov 8. doi: 10.1097/CMR.0000000000000937. PubMedAbstract available
TAIBO A, Paradela S, Suanzes-Hernandez J, Balboa-Barreiro V, et al Prognosis of CDKN2A germline mutation in patients with familial melanoma: a
systematic review and meta-analysis.
Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000920. PubMedAbstract available
GAMBICHLER T, Iordanou M, Becker JC, Susok L, et al Intratumoural and systemic inflammation as predictors for treatment response in
BRAF-mutated melanoma patients under targeted therapies.
Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000934. PubMedAbstract available
KIM HE, Kim J, Park HK, Lee JB, et al Correlations between inflammatory cytokine levels and degree of pigmentation in
acral melanomas.
Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000939. PubMedAbstract available
BENESCH MGK, Skitzki JJ Impact of anesthesia choice in cutaneous melanoma surgery.
Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000936. PubMedAbstract available
KOHL LM, Sumpter TL Melanomas and mast cells: an ambiguous relationship.
Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000932. PubMedAbstract available
October 2023
CAO Y, Afzal MZ, Gutmann EJ, Shirai K, et al Rare immune-related adverse events in a patient with metastatic melanoma: a case
report highlighting sarcoidosis-like reactions triggered by immune-checkpoint
inhibitors.
Melanoma Res. 2023 Oct 13. doi: 10.1097/CMR.0000000000000925. PubMedAbstract available
SADA I, Harada Y, Hiyama T, Mizukami M, et al Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in
patients with malignant melanoma.
Melanoma Res. 2023 Oct 2. doi: 10.1097/CMR.0000000000000933. PubMedAbstract available
RUBATTO M, Borriello S, Sciamarrelli N, Pala V, et al Exploring the role of epigenetic alterations and non-coding RNAs in melanoma
pathogenesis and therapeutic strategies.
Melanoma Res. 2023 Oct 2. doi: 10.1097/CMR.0000000000000926. PubMedAbstract available
PHAM JP, Dwyer L, Phan K, Menzies AM, et al Efficacy of topical diphencyprone for melanoma in-transit metastases: a
systematic review and meta-analysis.
Melanoma Res. 2023;33:434-436. PubMed
OZLUK AA, Karateke M, Sanli UA, Karaca B, et al Efficacy of local ablative therapies in patients with solid tumors treated with
immune checkpoint inhibitors and oligoprogression: a single-center analysis.
Melanoma Res. 2023;33:417-421. PubMedAbstract available
September 2023
BOUDREAU MW, Tonogai EJ, Schane CP, Xi MX, et al The combination of PAC-1 and entrectinib for the treatment of metastatic uveal
melanoma.
Melanoma Res. 2023 Sep 22. doi: 10.1097/CMR.0000000000000927. PubMedAbstract available
SEGURA S, Podlipnik S, Boada A, Marti RM, et al Melanoma-specific survival in worse in the elderly: a multicentric cohort study.
Melanoma Res. 2023 Sep 4. doi: 10.1097/CMR.0000000000000923. PubMedAbstract available
LIN Z, Shen H, Liu X, Ma W, et al Recent advances of artificial intelligence in melanoma clinical practice.
Melanoma Res. 2023 Sep 4. doi: 10.1097/CMR.0000000000000922. PubMedAbstract available
UEMATSU M, Nakajima H, Hosono A, Kiyohara H, et al Safety of immune checkpoint inhibitors after proton beam therapy in head and neck
mucosal melanoma: a case series.
Melanoma Res. 2023 Sep 4. doi: 10.1097/CMR.0000000000000924. PubMedAbstract available
August 2023
LUO S, Xie C, Lin N, Lin D, et al Cost-effectiveness analysis of an orphan drug-tebentafusp in patients with
metastatic uveal melanoma and a call for value-based pricing.
Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000919. PubMedAbstract available
MATTEI J, Trindade EN, Chedid MF Mucosal melanoma: from molecular landscape to current treatment strategies.
Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000916. PubMedAbstract available
MILEY DR, Andrews-Pfannkoch CM, Pulido JS, Erickson SA, et al Direct early growth response-1 knockdown decreases melanoma viability independent
of mitogen-activated extracellular signal-related kinase inhibition.
Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000921. PubMedAbstract available
LIU M, Lan Y, Zhang H, Zhang X, et al Telomere length is associated with increased risk of cutaneous melanoma: a
Mendelian randomization study.
Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000917. PubMedAbstract available
GJORUP CA, Pires da Silva I, Martin L, Stretch JR, et al Definitive treatment with PD-1 blockade and radiation therapy of unresected
primary desmoplastic melanoma of the nose.
Melanoma Res. 2023 Aug 3. doi: 10.1097/CMR.0000000000000905. PubMedAbstract available
AUGUSTYN K, Joseph J, Patel AB, Razmandi A, et al Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant
metastatic melanoma: management insights for clinical practice.
Melanoma Res. 2023 Aug 3. doi: 10.1097/CMR.0000000000000891. PubMedAbstract available
July 2023
GLINKINA KA, Teunisse AFAS, Gelmi MC, de Vries J, et al Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal
melanoma.
Melanoma Res. 2023 Jul 18. doi: 10.1097/CMR.0000000000000911. PubMedAbstract available
FELICI C, Passarelli A, Cafforio P, Racanelli V, et al Lenalidomide arrests cell cycle and modulates PD1-dependent downstream mTOR
intracellular signals in melanoma cells.
Melanoma Res. 2023 Jul 12. doi: 10.1097/CMR.0000000000000913. PubMedAbstract available
PELIZZARI G, Bertoli E, Buriolla S, Vitale MG, et al Estimating survival in patients with melanoma brain metastases: prognostic value
of lactate dehydrogenase.
Melanoma Res. 2023 Jul 3. doi: 10.1097/CMR.0000000000000907. PubMedAbstract available
June 2023
GIRONI LC, Esposto E, Zottarelli F, Giorgione R, et al Temporal correlation between the first melanoma and the first noncutaneous tumor
in CKDN2A genotyped patients.
Melanoma Res. 2023 Jun 21. doi: 10.1097/CMR.0000000000000906. PubMedAbstract available
HE K, Hong DS, Ke D, Kebriaei P, et al Durable control of metastases in an HLA-A2+ patient with refractory melanoma
after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case
report.
Melanoma Res. 2023 Jun 16. doi: 10.1097/CMR.0000000000000869. PubMedAbstract available
ASSEFA W, Muluye S, Assefa A, Alemu Y, et al A glimpse at locally advanced melanomas in the settings of poverty: pathologists
viewpoint.
Melanoma Res. 2023 Jun 13. doi: 10.1097/CMR.0000000000000909. PubMedAbstract available
KISISTOK J, Christensen DS, Rasmussen MH, Duval L, et al Analysis of circulating tumor DNA during checkpoint inhibition in metastatic
melanoma using a tumor-agnostic panel.
Melanoma Res. 2023 Jun 12. doi: 10.1097/CMR.0000000000000903. PubMedAbstract available
GARCIA-PEREZ O, Melgar-Vilaplana L, Sifaoui I, Garcia-Bello MA, et al Expression of angiogenic and lymphangiogenic genes in primary cutaneous melanoma:
relationship with angiolymphatic invasion and disease-free survival.
Melanoma Res. 2023 Jun 12. doi: 10.1097/CMR.0000000000000904. PubMedAbstract available
AMARA SV, Grbic N, Melson G, Brem CE, et al Assessment of lipid and pigment content in suspicious melanocytic lesions to
improve melanoma detection.
Melanoma Res. 2023 Jun 5. doi: 10.1097/CMR.0000000000000902. PubMedAbstract available
CHERSI F, Conforti C, Zalaudek I, Bazzacco G, et al Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a
metastatic melanoma patient.
Melanoma Res. 2023;33:262-263. PubMed
May 2023
AGNILA DRL, Huda TI, Eakins RA, Patel DN, et al Chemical features of melanoma tumor resident TRG CDR3s associated with better
survival probabilities.
Melanoma Res. 2023 May 23. doi: 10.1097/CMR.0000000000000899. PubMedAbstract available
SHELLENBERGER RA, Gowda S, Kurn H, Albright J, et al Vitamin D insufficiency and serum levels related to the incidence and stage of
cutaneous melanoma: a systematic review and meta-analysis.
Melanoma Res. 2023 May 18. doi: 10.1097/CMR.0000000000000897. PubMedAbstract available
PHAM JP, On L, Ardolino L, Hurwitz J, et al Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a
systematic review and meta-analysis.
Melanoma Res. 2023 May 18. doi: 10.1097/CMR.0000000000000900. PubMedAbstract available
YOO H, Park S, Kim SW Nodular type predominance of head and neck cutaneous malignant melanoma in Asian
populations leads to poor outcome and low survival.
Melanoma Res. 2023 May 18. doi: 10.1097/CMR.0000000000000901. PubMedAbstract available
MATTAVELLI I, Patuzzo R, Galeone C, Pelucchi C, et al Potential risk factors, clinicopathological features and determinants of survival
for multiple primary melanoma patients compared to single primary melanoma: a
large single-center Italian study.
Melanoma Res. 2023 May 8. doi: 10.1097/CMR.0000000000000898. PubMedAbstract available
OGATA D, Nishio S, Hatta N, Kaji T, et al Clinicopathological demographics of malignant melanomas of the vulva and vagina
in Japan.
Melanoma Res. 2023 May 8. doi: 10.1097/CMR.0000000000000894. PubMedAbstract available
April 2023
DIRVEN I, Vander Mijnsbrugge AS, Mignon S, Tijtgat J, et al Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as
immune-related adverse event in patients with metastatic melanoma and concurrent
chronic lymphocytic leukemia: a case series and literature review.
Melanoma Res. 2023 Apr 28. doi: 10.1097/CMR.0000000000000895. PubMedAbstract available
WONG CK, Dite GS, Spaeth E, Murphy NM, et al Melanoma risk prediction based on a polygenic risk score and clinical risk
factors.
Melanoma Res. 2023 Apr 24. doi: 10.1097/CMR.0000000000000896. PubMedAbstract available
MOHAMMADI A, Najafi S, Amini M, Baradaran B, et al B7H6 silencing increases chemosensitivity to dacarbazine and suppresses cell
survival and migration in cutaneous melanoma.
Melanoma Res. 2023 Apr 12. doi: 10.1097/CMR.0000000000000890. PubMedAbstract available
STATHAKI MI, Kapsoritakis N, Michelakis D, Anagnostopoulou E, et al The impact of sentinel lymph node mapping with hybrid single photon emission
computed tomography/computed tomography in patients with melanoma. Comparison to
planar radioisotopic lymphoscintigraphy.
Melanoma Res. 2023 Apr 12. doi: 10.1097/CMR.0000000000000893. PubMedAbstract available
BRUNSGAARD EK, Bowles TL, Asare EA, Grossmann K, et al Feasibility of personalized circulating tumor DNA detection in stage II and III
melanoma.
Melanoma Res. 2023 Apr 5. doi: 10.1097/CMR.0000000000000892. PubMedAbstract available
CYBULSKA-STOPA B, Piejko K, Ostaszewski K, Dziura R, et al Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and
pembrolizumab in advanced melanoma treatment.
Melanoma Res. 2023 Apr 3. doi: 10.1097/CMR.0000000000000885. PubMedAbstract available
March 2023
MANZANO JL, Martin-Liberal J, Fernandez-Morales LA, Benitez G, et al Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated
melanoma: DESCRIBE-AD real-world retrospective observational study.
Melanoma Res. 2023 Mar 28. doi: 10.1097/CMR.0000000000000888. PubMedAbstract available
VUILLAMY C, Arnault JP, Fumery M, Mortier L, et al Clostridium difficile infection and immune checkpoint inhibitor-induced colitis
in melanoma: 18 cases and a review of the literature.
Melanoma Res. 2023 Mar 27. doi: 10.1097/CMR.0000000000000878. PubMedAbstract available
YANG H, Zhou J, Li D, Zhou S, et al The inhibitory role of microRNA-141-3p in human cutaneous melanoma growth and
metastasis through the fibroblast growth factor 13-mediated mitogen-activated
protein kinase axis.
Melanoma Res. 2023 Mar 21. doi: 10.1097/CMR.0000000000000873. PubMedAbstract available
BOILEAU M, Templier C, Massip E, Dehoux C, et al Description of supportive care and feasibility of physical exercise program to
improve quality of life in advanced melanoma patients.
Melanoma Res. 2023 Mar 17. doi: 10.1097/CMR.0000000000000889. PubMedAbstract available
PIGNE T, Levy M, Ducharme O, Dutriaux C, et al Real-life use of trametinib after immunotherapy failure in BRAF wild-type
advanced melanoma.
Melanoma Res. 2023 Mar 15. doi: 10.1097/CMR.0000000000000884. PubMedAbstract available
BOILEAU M, Descarpentries C, Delzenne G, Trentesaux V, et al Clinical response under MEK inhibitor alone in metastatic melanoma with a novel
fusion involving the RAF1 gene.
Melanoma Res. 2023 Mar 3. doi: 10.1097/CMR.0000000000000882. PubMedAbstract available
JASSO-SOSA VY, Lino-Silva LS, Escobar-Jimenez MG, Galvan-Bustillos JR, et al Prognosis of polypoid melanoma: a comparative study with non-polypoid melanomas.
Melanoma Res. 2023 Mar 3. doi: 10.1097/CMR.0000000000000886. PubMedAbstract available
BERBERICH C, Mustafa M, Zhuwu Y, Gaa J, et al The influence of metastatic patterns and tumor load on therapeutic efficacy of
immunotherapy in patients with metastatic melanoma as determined by quantitative
PET-parameters using [18F]-fluorodeoxyglucose PET/computed tomography.
Melanoma Res. 2023 Mar 3. doi: 10.1097/CMR.0000000000000883. PubMedAbstract available
February 2023
KOMULAINEN J, Siiskonen H, Haimakainen S, Kanasuo E, et al Patients with a history of atopy have fewer cutaneous melanomas than those
without atopy: a cross-sectional study in 496 patients at risk of skin cancers.
Melanoma Res. 2023 Feb 28:e000887. doi: 10.1097/CMR.0000000000000887. PubMedAbstract available